Cite
Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score
MLA
Chakraborty, Rajshekhar, et al. “Abnormal Metaphase Cytogenetics Predicts Venous Thromboembolism in Myeloma: Derivation and Validation of the PRISM Score.” Blood, vol. 140, no. 23, Dec. 2022, pp. 2443–50. EBSCOhost, https://doi.org/10.1182/blood.2022015727.
APA
Chakraborty, R., Rybicki, L., Wei, W., Valent, J., Faiman, B. M., Samaras, C. J., Anwer, F., & Khorana, A. A. (2022). Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score. Blood, 140(23), 2443–2450. https://doi.org/10.1182/blood.2022015727
Chicago
Chakraborty, Rajshekhar, Lisa Rybicki, Wei Wei, Jason Valent, Beth M. Faiman, Christy J. Samaras, Faiz Anwer, and Alok A. Khorana. 2022. “Abnormal Metaphase Cytogenetics Predicts Venous Thromboembolism in Myeloma: Derivation and Validation of the PRISM Score.” Blood 140 (23): 2443–50. doi:10.1182/blood.2022015727.